Character Bio successfully raised $93 million in Series B funding to advance its precision medicine programs for age-related ocular diseases following promising developments since its Series A investment.

Information on the Target

Character Bio, a pioneering company in drug discovery and development, has garnered attention since our initial investment during their Series A round. The company’s approach is characterized by its direct partnerships with healthcare providers and patients, which facilitates the creation of comprehensive, real-world longitudinal datasets essential for therapeutic innovation. Their commitment to advancing precision medicine, particularly for age-related ocular diseases, is reflected in their recent $93 million Series B financing aimed at taking two lead programs into clinical development.

Following their initial funding, Character Bio has successfully matured their platform, advancing two proprietary programs for age-related macular degeneration (AMD) to peri-clinical stages. The company has also established a significant collaboration with Bausch and Lomb, a leading player in the field of ophthalmology, demonstrating the strength of their innovative and differentiated approach to drug development.

Industry Overview in the Target’s Specific Country

The drug development industry in the United States is increasingly focusing on utilizing real-world data to enhance precision medicine. The integration of longitudinal data assets has become a cornerstone for improving d